Literature DB >> 11307808

P-selectin antagonism causes dose-dependent venous thrombosis inhibition.

D D Myers1, R Schaub, S K Wrobleski, F J Londy, B A Fex, A M Chapman, L J Greenfield, T W Wakefield.   

Abstract

Inhibition of P-selectin by antibody or selectin antagonist decreases inflammation and thrombosis. This study evaluates the dose-response relationship using a selectin receptor antagonist. Eight male baboons (Papio anubis) underwent inferior vena caval thrombosis using a 6 h balloon occlusion model. Three animals received 500 microg/kg P-selectin antagonist (rPSGL-Ig) and five 1 mg/kg rPSGL-Ig with or without a non-anticoagulant dose of Dalteparin. These animals were compared to our published results in this model with 4 saline controls and 8 animals that received 4 mg/kg rPSGL-Ig. A statistically significant dose-response relationship existed between rPSGL-Ig dose and thrombosis (p < 0.01), and between rPSGL-Ig dose and spontaneous recanalization (p<0.05). Inflammatory assessment revealed decreased gadolinium enhancement in all rPSGL-Ig groups compared to previously reported control, despite no significant differences in inflammatory cell extravasation. No dose of rPSGL-Ig caused anticoagulation. Selectin antagonism results in a dose-dependent decrease in thrombosis and increase in spontaneous recanalization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307808

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  Recombinant P-selectin glycoprotein-ligand-1 delays thrombin-induced platelet aggregation: a new role for P-selectin in early aggregation.

Authors:  Jean-François Théorêt; Wissam Chahrour; Daniel Yacoub; Yahye Merhi
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 2.  Critical review of mouse models of venous thrombosis.

Authors:  Jose A Diaz; Andrea T Obi; Daniel D Myers; Shirley K Wrobleski; Peter K Henke; Nigel Mackman; Thomas W Wakefield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

Review 3.  New findings on venous thrombogenesis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Hamostaseologie       Date:  2016-11-23       Impact factor: 1.778

4.  P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.

Authors:  Jose A Diaz; Shirley K Wrobleski; Christine M Alvarado; Angela E Hawley; Nichole K Doornbos; Patrick A Lester; Suzan E Lowe; Joy E Gabriel; Karen J Roelofs; Peter K Henke; Robert G Schaub; Thomas W Wakefield; Daniel D Myers
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-05       Impact factor: 8.311

Review 5.  Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity.

Authors:  Mahin Behzadi Fard; Samaneh Behzadi Fard; Shahin Ramazi; Amir Atashi; Zahra Eslamifar
Journal:  Thromb J       Date:  2021-08-23

Review 6.  Do galectins play a role in venous thrombosis? a review.

Authors:  Jose A Diaz; Eduardo Ramacciotti; Thomas W Wakefield
Journal:  Thromb Res       Date:  2009-12-02       Impact factor: 3.944

7.  P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.

Authors:  Eduardo Ramacciotti; Daniel D Myers; Shirley K Wrobleski; K Barry Deatrick; Frank J Londy; John E Rectenwald; Peter K Henke; Robert G Schaub; Thomas W Wakefield
Journal:  Thromb Res       Date:  2009-12-04       Impact factor: 3.944

8.  Swine Model of Thrombotic Caval Occlusion Created by Autologous Thrombus Injection with Assistance of Intra-caval Net Knitting.

Authors:  Wan-Yin Shi; Shuang Wu; Lan-Yue Hu; Chang-Jian Liu; Jian-Ping Gu
Journal:  Sci Rep       Date:  2015-12-18       Impact factor: 4.379

Review 9.  The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.

Authors:  Benjamin A H Smith; Carolyn R Bertozzi
Journal:  Nat Rev Drug Discov       Date:  2021-01-18       Impact factor: 84.694

Review 10.  Immune Factors in Deep Vein Thrombosis Initiation.

Authors:  Ivan Budnik; Alexander Brill
Journal:  Trends Immunol       Date:  2018-05-16       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.